SAN
DIEGO CA–(Marketwire – Jun 29, 2012) – Medistem Inc. (PINKSHEETS: MEDS)
announced today notice of allowance from the United States Patent and Trademark
Office (USPTO) for a patent covering the use of fat stem cells, and cells
associated with fat stem cells for treatment of diseases related to a
dysfunctional immune system. Such diseases include multiple sclerosis, Type 1
diabetes, rheumatoid arthritis and lupus. The allowed patent, entitled
“Stem Cell Mediated Treg Activation/Expansion for Therapeutic Immune
Modulation” has the earliest priority date of December 2006.
DIEGO CA–(Marketwire – Jun 29, 2012) – Medistem Inc. (PINKSHEETS: MEDS)
announced today notice of allowance from the United States Patent and Trademark
Office (USPTO) for a patent covering the use of fat stem cells, and cells
associated with fat stem cells for treatment of diseases related to a
dysfunctional immune system. Such diseases include multiple sclerosis, Type 1
diabetes, rheumatoid arthritis and lupus. The allowed patent, entitled
“Stem Cell Mediated Treg Activation/Expansion for Therapeutic Immune
Modulation” has the earliest priority date of December 2006.
“We
have previously published that giving multiple sclerosis patients cells
extracted from their own fat tissue, which contains stem cells, appears to
confer clinical benefit in a pilot study,” said Thomas Ichim, CEO of
Medistem. “The current patent that has been allowed, in the broadest
interpretation of the claims, gives us exclusive rights to the use of specific
types of fat stem cell therapy for autoimmune diseases such as multiple sclerosis.”
have previously published that giving multiple sclerosis patients cells
extracted from their own fat tissue, which contains stem cells, appears to
confer clinical benefit in a pilot study,” said Thomas Ichim, CEO of
Medistem. “The current patent that has been allowed, in the broadest
interpretation of the claims, gives us exclusive rights to the use of specific
types of fat stem cell therapy for autoimmune diseases such as multiple sclerosis.”
Subsequent
to the filing of the patent application, Medistem together with collaborators
at the Lawson Health Sciences Research Institute, Canada, reported data that
fat tissue contains high numbers of T regulatory cells, a type of immune cell that
is capable of controlling autoimmunity.
to the filing of the patent application, Medistem together with collaborators
at the Lawson Health Sciences Research Institute, Canada, reported data that
fat tissue contains high numbers of T regulatory cells, a type of immune cell that
is capable of controlling autoimmunity.
..
Please note that all comments are moderated.
So that you can be kept up to date with MS news
Click here to: REGISTER – for our weekly e-Newsletter
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews